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A B S T R A CT  
Use of antisense oligonucleotides of the type 3′-(N)x-AAAUUUG-(N)x-5′ against slippery sequence  
and polynucleotides against pseudoknots forming sequences of SARS-CoV-2 RNA would block the 
first translation of ORF1a and ORF1b and hence dwindle the virus replication. It is easy to synthesize 
and deliver the antisense oligonucleotides to the target by directly injecting the nano formulation into 
the blood. 
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1 Introduction 
COVID-19 public-health emergency is caused by the outbreak of Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2).  While it is important to investing time to search the origins of the pandemic 
(1-3) it is the prime need of the moment to find out remedy against the outbreak and it is the molecular 
and biochemical mechanisms of multiplication of the virus would help us better than any other ways. 
2 Current Therapeutic Approaches 
Angiotensin-converting enzyme II (ACE2) expression is enhanced by SARS-CoV-2 infection (4).  
Repression of ACE2 gene by EZH2-mediated H3K27me3 modifications of ACE2 promoter could be a 
targeted for prevention and adjuvant therapy of COVID-19. ACE inhibitors or angiotensin receptor 
blockers would be helpful for patients to fight COVD-19 (4, 5). Non-specific medicines, including 
antimalarial and broad spectrum antibiotics are being used in many clinics. That the convalescent plasma 
(CP) would benefit COVID-19 patients along with antivirals is emerging. However, without control subject 
it is not clear yet although within three days of CP therapy patients exhibited improved clinical symptoms 
CP was given within two weeks of symptom onset (6-8). 
3 Mechanism of Synthesis of Virus Subparticles 
Prevailing knowledge based on studies with viral replication processes is; after the entry into the host cell, 
translation of ORF 1a and 1b into polyproteins Pp1a (4382 aas) and Pp1ab (7073 aas) is the primary 
function of the guest genome. Both the polyproteins then cleaved into fifteen non-structural proteins 
(nsps), which assemble and form the replication-transcription complex (RTC). ORF1b is translated by 
ribosome shifting one nucleotide in the −1 direction, from the ORF1a reading frame into ORF1b reading 
frame (reviewed in Tan et al.; 9). This mechanism of repositioning is facilitated by two RNA elements; (i) 
a 5′-UUUAAAC-3′ heptanucleotide slippery sequence (10), and (ii) RNA pseudoknot structure (see 
figures S1 and S2; 11). After the formation of RTC the full-length positive strand of genomic RNA 
transcribes to form a full-length negative-strand template for the synthesis of new genomic RNAs and 
overlapping subgenomic negative-strand templates. These subgenomic mRNAs are then transcribed and 
translated to produce the structural and accessory proteins. Several heterologous nuclear ribonucleoproteins 
(hnRNA) family members (hnRNPA1, PTB, SYN-CRYP) have been found to be essential for efficient 
RNA replication (9, 11, 12). 
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Formation of the cap structure of eukaryotic host and virus mRNAs basically requires three successive 
enzymatic reactions (13). Removal of the the γ-phosphate group from the 5′-triphosphate end (pppN) of 
the newly transcribed mRNA chain to generate the diphosphate 5′-ppN by RNA 5′-triphosphatase (RTP) 
is initial reaction. Then, RNA-guanylyltransferase transfers a GMP to the 5′-diphosphate end to produce 
the cap core structure (GpppN). Finally, guanine-N7 methyltransferase (GNMT) methylates the attached 
GMP (capping) at the N7 position to produce a cap-0 structure (me7GpppN). The 2′-O of ribose of the 
first and second nucleotides of the mRNA in higher eukaryotes and their viruses are additionally methylated. 
The responsible enzyme is ribose 2′-O-MT to form cap-1 and cap-2 structures, respectively (14, 15; see the 
supplementary figure S1). Ribose 2′-O-methylation of viral RNA cap provides a mechanism for viruses to 
escape host immune recognition (16-18). 
Cap-0 reaction is mediated by the C-terminal domain of CoV nsp14 (19) using S-Adenosylmethionine 
(SAM) as the methyl group donor (see supplementary figure S1). Conversion of cap-0 to cap-1 structures 
involves nsp16 that acts as a 2′-O-MT and forms a complex with nsp10 that appears to be required for 
efficient binding to SAM and the RNA substrate. Interestingly, SARS-CoV nsp10 plays an essential role in 
the specific binding of nsp16 to m7GpppA-capped RNA (first nucleotide is adenine). The crystal structure 
of the heterodimer of nsp16/nsp10 with bound methyl donor SAM showed that nsp10 may stabilize the 
SAM-binding pocket and extend the RNA-binding groove of nsp16 (20, 21). Thus, blocking the translation 
of the virus SARS-CoV-2 mRNA definitely serves the purpose. Use of non-specific drugs would complicate 
the disease keeping the virus in dormant stage with a chance to relapse by re-activation of the pathogen and 
outbreak of the disease. Efficacy of Chloroquine (CQ) and a less toxic derivative of CQ, 
Hydroxychloroquine (HCQ) against malaria provoked some research groups around the globe and in many 
clinics, it has been in use against COVID-19 (see supplementary manuscript/letter that I wrote to WHO). 
4 Recommendation for Target Specific Convenient Therapy 
In view of this, and to obtain toxicity free therapy of COVID-19 patients my recommendation is to 
conjointly use: (i) A oligonucleotide against the 5′-UUUAAAC-3′ heptanucleotide slippery sequence, and 
(ii) dismantling the pseudoknot preventing the pairing of matching sequences/RNA dimerization (22). 
Oligonucleotide of the antisense-type 3′-(N)x-AAAUUUG-(N)x-5′ [where N is any one of the A, U, G, C 
and x = 8 to 10] will block the slippery sequence and antisense oligonucleotides against pseudoknots 
forming sequences (22-24) may stop the 
translation of the viral RNA by ribosome shifting. 
The polynucleotides can easily be design 
synthesize and delivered by well-tailored 
nanoparticle carriers. Ligands like EGF/folate 
attached with nanoparticles surface 
(oligonucleotides loaded) would easily be delivered 
to the affected tissues by ligand-receptor complex 
formation where there is overexpression of the 
cognate receptors, including EGFR/CD44 and 
subsequent endocytosis will bring them into the 
sites of action (25, 26). See figure 1 for the overall 
procedure in brief. 
Figure 1: Source of the viral RNA pseudoknots:  
https://www.researchgate.net/publication/327750579_RNA_Structure-
A_Neglected_Puppet_Master_for_the_Evolution_of_Virus_and_Host_Immunity/figures?lo=1  
Legends to the figure: Schematic image depicts the procedure of possible antisense oligonucleotide (ON) therapy of COVID-19. ON 
encapsulated NPs with surface tagged ligand (EGF) may directly injected (intravenous) to the circulation. It will come to the lung and bind to 
cells by EGF-EGFR complex formation.  Endocytosis of the NPs will release the ONs and specific binding will block the virus RNA 
translation. 
It could be tested within seven days against lung cancer cell line or animal model. 
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5 Caution and Secondary Benefit 
Biodegradable nanoparticles from a variety of materials, including proteins, polysaccharides and synthetic 
biodegradable polymers should be used.  If the proteins for synthesizing nanoparticles would mimic the 
virus spike protein (S); the system may develop antibody against S. 
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